Reference : Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein...
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/76022
Le medicament du mois. Everolimus (RAD001/Afinitor) dans le traitement du cancer du rein métastatique.
French
[en] Everolimus (RAD001/Afinitor) in the treatment of metastatic renal cell carcinoma
Gennigens, Christine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Sautois, Brieuc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Jerusalem, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
2010
Revue Médicale de Liège
Hopital de Baviere
65
4
212-6
Yes (verified by ORBi)
0370-629X
Liège
Belgique
[en] Carcinoma, Renal Cell/drug therapy/metabolism/secondary ; Evidence-Based Medicine ; Humans ; Immunosuppressive Agents/adverse effects/pharmacology/therapeutic use ; Intracellular Signaling Peptides and Proteins/metabolism ; Kidney Neoplasms/drug therapy/metabolism/secondary ; Protein-Serine-Threonine Kinases/metabolism ; Randomized Controlled Trials as Topic ; Sirolimus/adverse effects/analogs & derivatives/pharmacology/therapeutic use ; Treatment Outcome
[en] Renal cell carcinoma accounts for 3% of all malignant tumours. Until a few years ago, immunotherapy (interferon and/or interleukin-2) was the only approved option in the metastatic setting. Better knowledge of renal cell cancer biology drew attention on the fundamental role of angiogenesis. Several strategies targeting angiogenesis have been developed including VEGF ("Vascular Endothelial Growth Factor") and VEGFR inhibitors. They are now the usual treatment in first line. Until recently, no standard treatment was available after failure under or after these inhibitors. Everolimus (Afinitor), a mTOR ("mammalian Target Of Rapamycin") inhibitor, has just been validated and reimbursed in this setting. In this paper, we will review the mechanism of action and the clinical results of everolimus.
http://hdl.handle.net/2268/76022

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Everolimus.pdfPublisher postprint200.93 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.